Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors
Cancer · 2025
DOI: 10.1002/cncr.70163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Michael A Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Receptor Antagonists. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, American Cancer Society, NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Management of metastatic prostate cancer often requires combining androgen deprivation therapy (ADT) with novel androgen receptor signaling inhibitors (ARSIs). Although these agents improve survival, older patients may face acute care utilization from medication burden, reflected in polypharmacy and nonadherence.
Methods
Using SEER‐Medicare data, the authors identified patients ≥66 years old with de novo metastatic prostate cancer prescribed abiraterone, enzalutamide, or apalutamide (2010–2017). Polypharmacy was defined by the Youden index (≥8 medications). ARSI adherence was measured by medication possession ratio (≥0.8) from initiation to discontinuation, assessed over 6 months. Acute care use was defined as any inpatient hospitalization or emergency visit within 6 months. Demographic characteristics were compared by t ‐tests/χ 2 . Negative binomial regression estimated incidence rate ratios (IRRs) for acute care use.
Results
Among 2697 patients (mean age, 75 years), most were White (80.3%), married (63.1%), and received prior ADT (85.3%). Polypharmacy was present in 50.6% of patients before ARSI initiation, whereas ARSI nonadherence in the 6 months post‐initiation was 34.0%. Polypharmacy and adherence were not significantly associated. In adjusted analyses controlling for demographic, clinical, and treatment factors, both polypharmacy (IRR, 1.59; 95% confidence interval [CI], 1.28–1.98) and ARSI nonadherence (IRR 2.50; 95% CI, 2.00–3.03) independently prognosticated higher acute care use.
Conclusions
Medication burden, as characterized by suboptimal adherence and polypharmacy, is an independent risk factor for acute care use among older adults initiating ARSI treatment for metastatic prostate cancer. These findings highlight an opportunity for potential interventions to reduce downstream acute care use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USA.
- Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
ORCID-Profile: Michael A Liu, Dawn L Hershman
Förderung
- NCI NIH HHS
- American Cancer Society
- NIH HHS
- National Institutes of Health
Zitieren
APA
Liu, M. A., Raghunathan, R., Runcie, K., Wooster, M., Wang, S., Wright, J. D., Wei, A. Z., Stein, M., & Hershman, D. L. (2025). Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors. Cancer. https://doi.org/10.1002/cncr.70163
Vancouver
Liu MA, Raghunathan R, Runcie K, Wooster M, Wang S, Wright JD, et al. Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors. Cancer. 2025. doi:10.1002/cncr.70163
BibTeX
@article{Liu2025,
author = {Liu, Michael A and Raghunathan, Rohit and Runcie, Karie and Wooster, Margaux and Wang, Shikun and Wright, Jason D and Wei, Alexander Z and Stein, Mark and Hershman, Dawn L},
title = {Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.70163}
}
EUVIMED